Autoimmune diseases other than lupus share common anti-DNA idiotypes

Shoenfeld, Yehuda; Ben-Yehuda, O.; Messinger, Yoav; Z, Bentwitch; Rauch, Joyce; Isenberg, D; Gadoth, Natan

doi:10.1016/0165-2478(88)90043-0

Cited by 48 publications

(52 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…including MBP to the inflammation related to autoimmune reactions [43,[113][114][115]. Increased levels of Abs and oligoclonal IgGs in the cerebrospinal fluid together with clonal B cell accumulation in the CSF and lesions of MS patients are among the main evidences of MS [115].…”

Section: Lupus 70mentioning

confidence: 99%

Catalytic Antibodies in Norm and Systemic Lupus Erythematosus

Nevinsky¹

2017

Lupus

321

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is known as a systemic polyethiologic diffuse autoimmune disease characterized by connective tissue disorganization and the paramount damage of skin and visceral capillaries. Usually, SLE symptoms include high fever, hair loss, mouth ulcers, chest pain, swollen lymph nodes, painful and swollen joints, increased fatigue, and appearance of red rash more often on the face. The exact reason of SLE appearance is not really clear. Detection of catalytic Abs (abzymes) was shown to be the earliest indicator of different AI disease development. Some abzymes are cytotoxic and can play a dangerous negative role in the pathogenesis of AI diseases. SLE is characterized by the appearance of abzymes with several different catalytic functions including hydrolysis of peptides and proteins, DNA, RNA, and oligosaccharides. In addition, monoclonal SLE abzymes are characterized by extraordinary diversity in the affinity to the substrates, physicochemical and catalytic characteristics, optimal conditions of catalysis, cytotoxicity, etc. Production of abzymes in SLE mice is associated with changes in the differentiation of hematopoietic stem cells of bone marrow, increase in lymphocyte proliferation, and significant suppression of cell apoptosis in different organs. In this chapter, abzymes with different catalytic activities in SLE are described.

show abstract

Section: Lupus 70mentioning

confidence: 99%

Catalytic Antibodies in Norm and Systemic Lupus Erythematosus

Nevinsky¹

2017

Lupus

321

View full text Add to dashboard Cite

show abstract

“…This is of special interest, since the presence of anti-cardiolipin antibodies may identify a sub group of SLE patients who are predisposed to vascular oc clusion [43], perhaps due to the possible effects of these antibodies on vascular endothelium and platelets. In hu man PSS, this question, however, is still controversial, most probably depending on the patients selected for the study [38,44,45], Malia et al [44] described the presence of anti-cardiolipin antibodies in 20-25% of patients with systemic sclerosis associated with extensive visceral in volvement. Anti-cardiolipin antibodies may be involved in the pathogenesis of PSS by causing vascular damage through inhibition of prostacyclin production in vascular endothelium [46,47].…”

Section: Control Studiesmentioning

confidence: 99%

“…A similar pattern was also seen for antibodies to poly(I) and poly(G). Serological studies on scleroderma patients [38] have also revealed anti-poly[(dT); 50%]. and -less frequently -anti-poly(I).…”

Section: Control Studiesmentioning

confidence: 99%

Antinuclear Antibody Profile in UCD Line 200 Chickens: A Model for Progressive Systemic Sclerosis

Gruschwitz

Shoenfeld

Krupp

et al. 1993

Int Arch Allergy Immunol

View full text Add to dashboard Cite

The fully blown disease of human progressive systemic sclerosis (PSS, scleroderma) is serologically associated with the emergence of several types of autoantibodies, some of them regarded as more specific for scleroderma (e.g. Scl-70, anti-centromere) and some common also to other connective tissue diseases (e.g. anti-ssDNA). Since most patients suffering from PSS are not under medical control until clinical manifestations are fully established, only scarce data are available on the dynamics and clinical significance of autoantibodies in the very early stages of this systemic fibrotic disease. The University of California at Davis line 200 (UCD 200) of chickens spontaneously develop a PSS-like disorder with an acute inflammatory stage around 60 days after hatching, leading to fibrosis with fast progression. In order to address a possible correlation between the occurrence and titer of autoantibodies and the initial disease activity, we have chronologically investigated the presence and titer of autoantibodies directed against several human nuclear antigens in this animal strain. In UCD-200 chickens, we found a progressive increase in autoantibodies to histones, to ssDNA and – to a lesser degree – dsDNA with peaks at the age of 60 and 120 days, to poly(I) and poly(G) with a peak at 120 days and an elevation in anti-cardiolipin antibodies. Total immunoglobulin concentrations, anti-Ro, anti-La and anti-Sm showed no significant differences as compared to negative results in healthy normal controls. Our data reveal parallels in the antinuclear antibody (ANA) spectrum between UCD-200 chickens and human autoimmune collagen diseases, but do not reflect the typical ANA spectrum found in the foudroyant form of diffuse scleroderma. It still remains to be clarified whether these serum antibodies play an integral role in the pathogenesis of the scleroderma-like disease in the UCD-200 line.

show abstract

“…Even in the sera of healthy mammals the titers of anti-DNA Abs are detectable but vary significantly. Compared with healthy donors, concentrations of anti-DNA Abs are higher in patients with systemic lupus erythematosus (SLE) (36% of SLE patients), multiple sclerosis (17-18%), primary Sjogren's syndrome (18%), Hashimoto thyroiditis (23%), myasthenia gravis (6%), and rheumatoid arthritis (7%) (Shoenfeld et al, 1988). Many SLE anti-DNA Abs are directed against histone-DNA nucleosomal complexes appearing as a result of internucleosomal cleavage during apoptosis (Founel and Muller, 2002).…”

Section: Introductionmentioning

confidence: 99%

Antibodies against RNA hydrolyze RNA and DNA

Krasnorutskii

Buneva

Nevinsky

2008

J of Molecular Recognition

View full text Add to dashboard Cite

Immunization of animals with DNA leads to the production of anti-DNA antibodies (Abs) demonstrating both DNase and RNase activities. It is currently not known whether anti-RNA Abs can possess nuclease activities. In an attempt to address this question, we have shown that immunization of three rabbits with complex of RNA with methylated BSA (mBSA) stimulates production of IgGs with RNase and DNase activities belonging to IgGs, while polyclonal Abs from three non-immunized rabbits and three animals immunized with mBSA are catalytically inactive. Affinity chromatography of IgGs from the sera of autoimmune (AI) patients on DNA-cellulose usually demonstrates a number of fractions, all of which effectively hydrolyze both DNA and RNA, while rabbit catalytic IgGs were separated into Ab subfractions, some of which demonstrated only DNase activity, while others hydrolyzed RNA faster than DNA. The enzymic properties of the RNase and DNase IgGs from rabbits immunized with RNA distinguish them from all known canonical RNases and DNases and DNA- and RNA-hydrolyzing abzymes (Abzs) from patients with different AI diseases. In contrast to RNases and AI RNA-hydrolyzing Abs, rabbit RNase IgGs catalyze only the first step of the hydrolysis reaction but cannot hydrolyze the formed terminal 2',3'-cyclophosphate. The data indicate that Abzs of AI patients hydrolyzing nucleic acids in part may be Abs against RNA and its complexes with proteins.

show abstract

Autoimmune diseases other than lupus share common anti-DNA idiotypes

Cited by 48 publications

References 24 publications

Catalytic Antibodies in Norm and Systemic Lupus Erythematosus

Catalytic Antibodies in Norm and Systemic Lupus Erythematosus

Antinuclear Antibody Profile in UCD Line 200 Chickens: A Model for Progressive Systemic Sclerosis

Antibodies against RNA hydrolyze RNA and DNA

Contact Info

Product

Resources

About